RxDoctor Payments Data

Ismet Lukolic, MD

Gastroenterology · Seaford, DENPI 1275777039

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (60.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Olympus Corporation Of The Americas accounts for 67.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $3,857 and has fallen 96.5% since, to $137 in 2025.

$5,187in general payments, 2019–2025

Across 115 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$4K
  • AbbVie$498
  • Takeda Pharmaceuticals U.S.A., Inc.$256
  • Gilead$220
  • Olympus America Inc.$169
  • Pfizer$128
  • plus $409 from 9 others

What the payments were for

  • Travel & lodging$3,11060%
  • Food & beverage$2,06140%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,187 in reported general payments places this provider in the 65th percentile of 50 gastroenterology providers in Delaware.

See all gastroenterology providers in Delaware

Medicare billing

Part B allowed, 2024
$205,167
Medicare patients
773
Services billed
1,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$351,748
Humira(Cf) PenAdalimumab12$237,253
XifaxanRifaximin18$58,788
LinzessLinaclotide44$53,589
Mesalamine29$13,739
Omeprazole340$5,306
Pantoprazole Sodium337$4,623
Dexlansoprazole DrDexlansoprazole12$3,958
Lubiprostone22$3,567
Sucralfate77$2,110
Famotidine120$1,986
Ursodiol14$1,635
Spironolactone25$210
Hydroxyzine Hcl13$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$120$351,74812 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$22$58,78818 claims
AbbVieLinzess$498$53,58944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 gastroenterology providers in Delaware.

Other gastroenterology in Seaford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →